Center of Radiopharmacy, Institute of Energetic and Nuclear Research, Sao Paulo, SP 05508-000, Brazil.
Nucl Med Biol. 2011 Jan;38(1):113-20. doi: 10.1016/j.nucmedbio.2010.06.011. Epub 2010 Sep 1.
Several strategies on the development of radiopharmaceuticals have been employed. Bifunctional chelators seem to be a promising approach since high radiochemical yields as well as good in vitro and in vivo stability have been achieved. To date, neurotensin analogs have been radiolabeled using the (99m)Tc-carbonyl approach and none was described employing the bifunctional chelating agent technique.
The purpose of this study was to evaluate the radiochemical and biological behaviour of NT(8-13) analogue radiolabeled with (99m)Tc, using HYNIC and NHS-S-acetyl-MAG(3) as chelator agents.
Radiolabeling, in vitro stability toward cysteine and glutathione, partition coefficient and plasma protein binding were assessed for both radioconjugates. Biodistribution in healthy Swiss mice were carried out in order to evaluate the biological behaviour of the radiocomplexes.
Radiochemical yields were higher than 97% and no apparent instability toward transchelant agents was observed for both radioconjugates. A higher lipophilic character was observed for the radioconjugate labeled via MAG(3). The chelators seem to have no effect on the percentage of the radioconjugate bound to plasma proteins. A similar biological pattern was observed for both radioconjugates. Total blood, bone and muscle values revealed a slightly slower clearance for the radiocomplex labeled via MAG(3). Moreover, a remarkable liver and intestinal uptake was observed for the radiocomplex labeled via MAG(3) even at the later time points studied.
The high radiochemical yields achieved and the similar in vivo pattern found for both radioconjugates make them potential candidates for imaging tumors using nuclear medicine techniques.
已经采用了几种放射性药物的开发策略。双功能螯合剂似乎是一种很有前途的方法,因为已经实现了高放射化学产率以及良好的体外和体内稳定性。迄今为止,神经降压素类似物已经使用 (99m)Tc-羰基方法进行放射性标记,而没有使用双功能螯合剂技术进行描述。
本研究的目的是评估使用 HYNIC 和 NHS-S-乙酰基-MAG(3)作为螯合剂标记的 NT(8-13)类似物的放射化学和生物学行为。
评估了两种放射性缀合物的放射化学标记、对半胱氨酸和谷胱甘肽的体外稳定性、分配系数和血浆蛋白结合率。为了评估放射性复合物的生物学行为,在健康的瑞士小鼠中进行了生物分布研究。
放射化学产率均高于 97%,并且两种放射性缀合物均未观察到明显的转金属试剂不稳定性。通过 MAG(3)标记的放射性缀合物表现出更高的亲脂性。螯合剂似乎对与血浆蛋白结合的放射性缀合物的百分比没有影响。两种放射性缀合物表现出相似的生物学模式。总血液、骨骼和肌肉值表明,通过 MAG(3)标记的放射性复合物的清除速度稍慢。此外,通过 MAG(3)标记的放射性复合物在研究的后期时间点观察到明显的肝脏和肠道摄取。
高放射化学产率的实现以及两种放射性缀合物相似的体内模式使得它们成为使用核医学技术成像肿瘤的潜在候选物。